Profil
Michael L.
Babich served as President, Chief Executive Officer & Director at INSYS Therapeutics, Inc. from 2010 to 2015.
Prior to that, he was a Director at Cordex Pharma, Inc. in 2006.
He also served as a Director at Alliant Pharmaceuticals, Inc. Additionally, he was Chief Operating Officer & Director at InSys Therapeutics, Inc. from 2007 to 2011.
Babich received his undergraduate degree from the University of Illinois and his MBA from Kellogg School of Management.
Anciens postes connus de Michael L. Babich
| Sociétés | Poste | Fin |
|---|---|---|
| INSYS THERAPEUTICS, INC. | Directeur Général | 04/11/2015 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Directeur des opérations | 01/11/2010 |
Cordex Pharma, Inc.
 Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | 04/08/2006 |
Alliant Pharmaceuticals, Inc.
 Alliant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alliant Pharmaceuticals, Inc. developed and manufactured pharmaceutical products. The company was headquartered in Atlanta, GA. | Directeur/Membre du Conseil | - |
Formation de Michael L. Babich
| University of Illinois | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Cordex Pharma, Inc.
Cordex Pharma, Inc. Medical SpecialtiesHealth Technology Cordex Pharma, Inc. is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex Pharma was founded on February 9, 1996 and is headquartered in Philadelphia, PA. | Health Technology |
Alliant Pharmaceuticals, Inc.
Alliant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alliant Pharmaceuticals, Inc. developed and manufactured pharmaceutical products. The company was headquartered in Atlanta, GA. | Health Technology |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Health Technology |
